WGSGeneDx Holdings Corp.
$67.31-48% 1Y
$67.31
$34.5152 weeks$167.51
The financials
GeneDx Holdings Corp. by the numbers
GeneDx Holdings Corp. (WGS) reported revenue of $114M in Q2 2026 (quarter ended Jun 30, 2026), up 11% from the same quarter a year earlier. That came with a gross margin of 68% and net loss of $18M. For the full year FY2025, revenue was $428M (+40% year on year) and net income −$21M. Its largest product in Q2 2026 was Diagnostic Test Third Party Insurance at $95M, 83% of the disclosed total, well ahead of Diagnostic Test Institutional Customers at 14%. The next results filing is expected around Oct 27, 2026, the same week as a year ago.
| Income statement | Q2 2026 | Q2 2025 | Change |
|---|---|---|---|
| Revenue | $114M | $103M | +11% |
| Gross profit | $78M | $71M | +10% |
| Operating income | −$17M | $9.0M | to a loss |
| Net income | −$18M | $11M | to a loss |
| Diluted EPS | −$0.60 | $0.36 | to a loss |
| Product | Revenue | Share |
|---|---|---|
| Diagnostic Test Third Party Insurance | $95M | 83% |
| Diagnostic Test Institutional Customers | $16M | 14% |
| Product And Service Other | $2.6M | 2.2% |
| Diagnostic Test Self Pay | $1.0M | 0.9% |
Business segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Jun 2026Total $114.4M (+13%)
Diagnostic Test Self Pay grew +207% year on yearDiagnostic Test Institutional Customers -14% year on year
Segment Latestquarter on quarteryear on year
- Diagnostic Test Third Party Insurance$94.7M$94.7Mquarter on quarter +12%year on year +17%+12%+17%
- Diagnostic Test Institutional Customers$16.1M$16.1Mquarter on quarter +3.8%year on year -14%+3.8%-14%
- Product And Service Other$2.6M$2.6Mquarter on quarter +167%year on year -1.5%+167%-1.5%
- Diagnostic Test Self Pay$1.0M$1.0Mquarter on quarter +264%year on year +207%+264%+207%
On our screens:Most shorted stocks
Diagnostics & Research
Ranks #9 of 21 by RyuScore